Biopharmaceutical Industry in France: Market Research Reports, Statistics and Analysis

Company Report: Biopharmaceutical In The United States And Europe ...

... Less profitable there due to the lack of sales synergies with a growth hormone, unlike in europe) and apokyn. Ipsen also targets a partnership in the french primary care business, where pending risks ...

Company Report: Biopharmaceutical In Japan And France For Year 20 ...

... Signed since january 1, 2012 to use the eb66 cell line for the production of vaccines and monoclonal antibodies, two of which are commercial licenses. For the viva|screen Technology (monoclonal ...

Intercell Ag - Company Report For Year 2013

... And production of rare, fully human monoclonal antibodies are offered by vivalis. Through these programs, vivalis receives payments associated with the funding of discovery research, an upfront payment, clinical ...

Company Report: Biopharmaceutical In France For Year 2012

... For ib1001, a human recombinant factor ix (long-term study on adults, an extension of the study used for the filing in q4-11, and paediatric study in europe), due to a high rate of patients developing ...

Company Report: Biopharmaceutical In Japan And France For Year 20 ...

... Stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, vlps and recombinant proteins, including monoclonal antibodies ...

Company Report: Biopharmaceutical In Japan And France For Year 20 ...

Company Report: Biopharmaceutical In Japan And France For Year 20 ...

... Operational and (iii) the development of a proprietary antibody portfolio that will be licensed before clinical phases are launched. After laying foundations with major strategic assets, we are today ready ...

The French Antibody Industry Brief

... An a e me o birth as well as ear y appearance of mucosal antibodies in breast milk. This offers the possibility of protecting the infant against pertussis from birth until immunity is achieved ...

Biopharmaceutical In The United States, France And Canada : Innov ...

... Transgenic plants. This technology has the potential to offer speed and cost advantages over competitive tech- nologies. It can deliver a vaccine for testing in less than a month after the identification ...